Loading…
Weight loss outcomes with semaglutide based on diabetes severity using the individualized metabolic surgery score
Semaglutide demonstrated inferior weight loss responses in patients with type 2 diabetes (T2D) compared to patients with obesity without T2D. The individualized metabolic surgery (IMS) score was validated to predict T2D remission after bariatric surgery. The parameters of the IMS are HbA1c (
Saved in:
| Published in: | EClinicalMedicine 2024-06, Vol.72, p.102625-102625, Article 102625 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | |
|---|---|
| cites | cdi_FETCH-LOGICAL-c367t-1ac78de25aabbc6f02fbb8e94c957fa0919eb2cb9de50f4f7d51698d38202b8c3 |
| container_end_page | 102625 |
| container_issue | |
| container_start_page | 102625 |
| container_title | EClinicalMedicine |
| container_volume | 72 |
| creator | Ghusn, Wissam Anazco, Diego Fansa, Sima Tama, Elif Cifuentes, Lizeth Gala, Khushboo Calderon, Gerardo Collazo-Clavell, Maria L. Hurtado, Maria D. Acosta, Andres |
| description | Semaglutide demonstrated inferior weight loss responses in patients with type 2 diabetes (T2D) compared to patients with obesity without T2D. The individualized metabolic surgery (IMS) score was validated to predict T2D remission after bariatric surgery. The parameters of the IMS are HbA1c ( |
| doi_str_mv | 10.1016/j.eclinm.2024.102625 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11096862</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S2589537024002049</els_id><sourcerecordid>3056666514</sourcerecordid><originalsourceid>FETCH-LOGICAL-c367t-1ac78de25aabbc6f02fbb8e94c957fa0919eb2cb9de50f4f7d51698d38202b8c3</originalsourceid><addsrcrecordid>eNp9kU1r3DAQhk1paEKSf1CKjr3sVpItWb60lNAvCPSS0KPQx9g7i20lkrxh--ur4DSkl-oyQvPMO-J9q-oto1tGmfyw34IbcZ62nPKmPHHJxavqjAvVbUTd0tcv7qfVZUp7SimnjeokfVOd1qoVklF5Vt3_Ahx2mYwhJRKW7MIEiTxg3pEEkxnGJaMHYk0CT8JMPBoLuSAJDhAxH8mScB5I3gHB2eMB_WJG_F3oCbKxYURH0hIHiEeSXIhwUZ30Zkxw-VTPq9uvX26uvm-uf377cfX5euNq2eYNM65VHrgwxlone8p7axV0jetE2xvasQ4sd7bzIGjf9K0XTHbK16pYYpWrz6tPq-7dYifwDuYczajvIk4mHnUwqP_tzLjTQzhoxmgnleRF4f2TQgz3C6SsJ0wOxtHMEJakaypkOYI1BW1W1MViZIT-eQ-j-jExvddrYvoxMb0mVsbevfzj89DffArwcQWgOHVAiDo5hNmBxwguax_w_xv-AAaSrX8</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3056666514</pqid></control><display><type>article</type><title>Weight loss outcomes with semaglutide based on diabetes severity using the individualized metabolic surgery score</title><source>BACON - Elsevier - GLOBAL_SCIENCEDIRECT-OPENACCESS</source><source>PubMed Central</source><creator>Ghusn, Wissam ; Anazco, Diego ; Fansa, Sima ; Tama, Elif ; Cifuentes, Lizeth ; Gala, Khushboo ; Calderon, Gerardo ; Collazo-Clavell, Maria L. ; Hurtado, Maria D. ; Acosta, Andres</creator><creatorcontrib>Ghusn, Wissam ; Anazco, Diego ; Fansa, Sima ; Tama, Elif ; Cifuentes, Lizeth ; Gala, Khushboo ; Calderon, Gerardo ; Collazo-Clavell, Maria L. ; Hurtado, Maria D. ; Acosta, Andres</creatorcontrib><description>Semaglutide demonstrated inferior weight loss responses in patients with type 2 diabetes (T2D) compared to patients with obesity without T2D. The individualized metabolic surgery (IMS) score was validated to predict T2D remission after bariatric surgery. The parameters of the IMS are HbA1c (<7%), insulin use, T2D medications and T2D duration. We aim to assess weight loss outcomes of semaglutide based on IMS score in patients with obesity and T2D.
This is a retrospective multicentered cohort study of patients with T2D and BMI≥ 27 kg/m2 taking ≥1 mg of semaglutide recruited from January 2020 to December 2022. We excluded patients with a history of bariatric surgery or taking other anti-obesity medications. IMS was calculated at baseline and patients weight change was recorded at baseline, 3, 6, 9 and 12 months. IMS was classified as mild (0–24.9 points), moderate (25–94.9 points), and severe (95–180 points). Analysis was performed based on IMS score quartiles and combination of Mild-Moderate vs Severe categories. We performed mixed linear regression models including age, sex, and baseline weight to assess associations between IMS categories with total body weight loss percentage (TBWL%).
We included 297 patients (42% female, mean age 62 ± 12 years) in the analysis. At 12 months, there was a stepwise decrease in weight loss outcomes when comparing patients by IMS quartiles (LS mean TBWL%± SE): 8.8 ± 0.8% vs 6.9 ± 0.8% vs 5.7 ± 0.9% vs 5.0 ± 0.8%. In the mixed linear model, patients in the mild-moderate category achieved significantly superior weight loss outcomes (LS mean TBWL± SE: −8.3 ± 0.7%) than patients in the severe category (−5.5 ± 0.6%; difference: −2.9, 95% CI: −5.2 to −0.5, p = 0.006) at 12 months. There was no significant difference in glycemic improvement regardless of IMS severity at baseline.
In our cohort, lower IMS severity was associated with more weight loss in patients with obesity and T2D. Further studies are needed to understand T2D severity and its effect on semaglutide outcomes.
Beyond payment to the research staff by Mayo Clinic, this research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.</description><identifier>ISSN: 2589-5370</identifier><identifier>EISSN: 2589-5370</identifier><identifier>DOI: 10.1016/j.eclinm.2024.102625</identifier><identifier>PMID: 38756106</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Diabetes ; GLP-1 receptor agonists ; Individualized metabolic surgery score ; Obesity ; Semaglutide</subject><ispartof>EClinicalMedicine, 2024-06, Vol.72, p.102625-102625, Article 102625</ispartof><rights>2024 The Authors</rights><rights>2024 The Authors.</rights><rights>2024 The Authors 2024</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c367t-1ac78de25aabbc6f02fbb8e94c957fa0919eb2cb9de50f4f7d51698d38202b8c3</cites><orcidid>0009-0009-7595-9113 ; 0000-0002-9389-6795 ; 0000-0002-2322-7334 ; 0000-0003-1829-7001 ; 0000-0003-2286-489X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11096862/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11096862/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,733,786,790,891,27957,27958,53827,53829</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38756106$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ghusn, Wissam</creatorcontrib><creatorcontrib>Anazco, Diego</creatorcontrib><creatorcontrib>Fansa, Sima</creatorcontrib><creatorcontrib>Tama, Elif</creatorcontrib><creatorcontrib>Cifuentes, Lizeth</creatorcontrib><creatorcontrib>Gala, Khushboo</creatorcontrib><creatorcontrib>Calderon, Gerardo</creatorcontrib><creatorcontrib>Collazo-Clavell, Maria L.</creatorcontrib><creatorcontrib>Hurtado, Maria D.</creatorcontrib><creatorcontrib>Acosta, Andres</creatorcontrib><title>Weight loss outcomes with semaglutide based on diabetes severity using the individualized metabolic surgery score</title><title>EClinicalMedicine</title><addtitle>EClinicalMedicine</addtitle><description>Semaglutide demonstrated inferior weight loss responses in patients with type 2 diabetes (T2D) compared to patients with obesity without T2D. The individualized metabolic surgery (IMS) score was validated to predict T2D remission after bariatric surgery. The parameters of the IMS are HbA1c (<7%), insulin use, T2D medications and T2D duration. We aim to assess weight loss outcomes of semaglutide based on IMS score in patients with obesity and T2D.
This is a retrospective multicentered cohort study of patients with T2D and BMI≥ 27 kg/m2 taking ≥1 mg of semaglutide recruited from January 2020 to December 2022. We excluded patients with a history of bariatric surgery or taking other anti-obesity medications. IMS was calculated at baseline and patients weight change was recorded at baseline, 3, 6, 9 and 12 months. IMS was classified as mild (0–24.9 points), moderate (25–94.9 points), and severe (95–180 points). Analysis was performed based on IMS score quartiles and combination of Mild-Moderate vs Severe categories. We performed mixed linear regression models including age, sex, and baseline weight to assess associations between IMS categories with total body weight loss percentage (TBWL%).
We included 297 patients (42% female, mean age 62 ± 12 years) in the analysis. At 12 months, there was a stepwise decrease in weight loss outcomes when comparing patients by IMS quartiles (LS mean TBWL%± SE): 8.8 ± 0.8% vs 6.9 ± 0.8% vs 5.7 ± 0.9% vs 5.0 ± 0.8%. In the mixed linear model, patients in the mild-moderate category achieved significantly superior weight loss outcomes (LS mean TBWL± SE: −8.3 ± 0.7%) than patients in the severe category (−5.5 ± 0.6%; difference: −2.9, 95% CI: −5.2 to −0.5, p = 0.006) at 12 months. There was no significant difference in glycemic improvement regardless of IMS severity at baseline.
In our cohort, lower IMS severity was associated with more weight loss in patients with obesity and T2D. Further studies are needed to understand T2D severity and its effect on semaglutide outcomes.
Beyond payment to the research staff by Mayo Clinic, this research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.</description><subject>Diabetes</subject><subject>GLP-1 receptor agonists</subject><subject>Individualized metabolic surgery score</subject><subject>Obesity</subject><subject>Semaglutide</subject><issn>2589-5370</issn><issn>2589-5370</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNp9kU1r3DAQhk1paEKSf1CKjr3sVpItWb60lNAvCPSS0KPQx9g7i20lkrxh--ur4DSkl-oyQvPMO-J9q-oto1tGmfyw34IbcZ62nPKmPHHJxavqjAvVbUTd0tcv7qfVZUp7SimnjeokfVOd1qoVklF5Vt3_Ahx2mYwhJRKW7MIEiTxg3pEEkxnGJaMHYk0CT8JMPBoLuSAJDhAxH8mScB5I3gHB2eMB_WJG_F3oCbKxYURH0hIHiEeSXIhwUZ30Zkxw-VTPq9uvX26uvm-uf377cfX5euNq2eYNM65VHrgwxlone8p7axV0jetE2xvasQ4sd7bzIGjf9K0XTHbK16pYYpWrz6tPq-7dYifwDuYczajvIk4mHnUwqP_tzLjTQzhoxmgnleRF4f2TQgz3C6SsJ0wOxtHMEJakaypkOYI1BW1W1MViZIT-eQ-j-jExvddrYvoxMb0mVsbevfzj89DffArwcQWgOHVAiDo5hNmBxwguax_w_xv-AAaSrX8</recordid><startdate>20240601</startdate><enddate>20240601</enddate><creator>Ghusn, Wissam</creator><creator>Anazco, Diego</creator><creator>Fansa, Sima</creator><creator>Tama, Elif</creator><creator>Cifuentes, Lizeth</creator><creator>Gala, Khushboo</creator><creator>Calderon, Gerardo</creator><creator>Collazo-Clavell, Maria L.</creator><creator>Hurtado, Maria D.</creator><creator>Acosta, Andres</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>6I.</scope><scope>AAFTH</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0009-0009-7595-9113</orcidid><orcidid>https://orcid.org/0000-0002-9389-6795</orcidid><orcidid>https://orcid.org/0000-0002-2322-7334</orcidid><orcidid>https://orcid.org/0000-0003-1829-7001</orcidid><orcidid>https://orcid.org/0000-0003-2286-489X</orcidid></search><sort><creationdate>20240601</creationdate><title>Weight loss outcomes with semaglutide based on diabetes severity using the individualized metabolic surgery score</title><author>Ghusn, Wissam ; Anazco, Diego ; Fansa, Sima ; Tama, Elif ; Cifuentes, Lizeth ; Gala, Khushboo ; Calderon, Gerardo ; Collazo-Clavell, Maria L. ; Hurtado, Maria D. ; Acosta, Andres</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c367t-1ac78de25aabbc6f02fbb8e94c957fa0919eb2cb9de50f4f7d51698d38202b8c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Diabetes</topic><topic>GLP-1 receptor agonists</topic><topic>Individualized metabolic surgery score</topic><topic>Obesity</topic><topic>Semaglutide</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ghusn, Wissam</creatorcontrib><creatorcontrib>Anazco, Diego</creatorcontrib><creatorcontrib>Fansa, Sima</creatorcontrib><creatorcontrib>Tama, Elif</creatorcontrib><creatorcontrib>Cifuentes, Lizeth</creatorcontrib><creatorcontrib>Gala, Khushboo</creatorcontrib><creatorcontrib>Calderon, Gerardo</creatorcontrib><creatorcontrib>Collazo-Clavell, Maria L.</creatorcontrib><creatorcontrib>Hurtado, Maria D.</creatorcontrib><creatorcontrib>Acosta, Andres</creatorcontrib><collection>ScienceDirect Open Access Titles</collection><collection>Elsevier:ScienceDirect:Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>EClinicalMedicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ghusn, Wissam</au><au>Anazco, Diego</au><au>Fansa, Sima</au><au>Tama, Elif</au><au>Cifuentes, Lizeth</au><au>Gala, Khushboo</au><au>Calderon, Gerardo</au><au>Collazo-Clavell, Maria L.</au><au>Hurtado, Maria D.</au><au>Acosta, Andres</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Weight loss outcomes with semaglutide based on diabetes severity using the individualized metabolic surgery score</atitle><jtitle>EClinicalMedicine</jtitle><addtitle>EClinicalMedicine</addtitle><date>2024-06-01</date><risdate>2024</risdate><volume>72</volume><spage>102625</spage><epage>102625</epage><pages>102625-102625</pages><artnum>102625</artnum><issn>2589-5370</issn><eissn>2589-5370</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><notes>Contributed equally to this manuscript.</notes><abstract>Semaglutide demonstrated inferior weight loss responses in patients with type 2 diabetes (T2D) compared to patients with obesity without T2D. The individualized metabolic surgery (IMS) score was validated to predict T2D remission after bariatric surgery. The parameters of the IMS are HbA1c (<7%), insulin use, T2D medications and T2D duration. We aim to assess weight loss outcomes of semaglutide based on IMS score in patients with obesity and T2D.
This is a retrospective multicentered cohort study of patients with T2D and BMI≥ 27 kg/m2 taking ≥1 mg of semaglutide recruited from January 2020 to December 2022. We excluded patients with a history of bariatric surgery or taking other anti-obesity medications. IMS was calculated at baseline and patients weight change was recorded at baseline, 3, 6, 9 and 12 months. IMS was classified as mild (0–24.9 points), moderate (25–94.9 points), and severe (95–180 points). Analysis was performed based on IMS score quartiles and combination of Mild-Moderate vs Severe categories. We performed mixed linear regression models including age, sex, and baseline weight to assess associations between IMS categories with total body weight loss percentage (TBWL%).
We included 297 patients (42% female, mean age 62 ± 12 years) in the analysis. At 12 months, there was a stepwise decrease in weight loss outcomes when comparing patients by IMS quartiles (LS mean TBWL%± SE): 8.8 ± 0.8% vs 6.9 ± 0.8% vs 5.7 ± 0.9% vs 5.0 ± 0.8%. In the mixed linear model, patients in the mild-moderate category achieved significantly superior weight loss outcomes (LS mean TBWL± SE: −8.3 ± 0.7%) than patients in the severe category (−5.5 ± 0.6%; difference: −2.9, 95% CI: −5.2 to −0.5, p = 0.006) at 12 months. There was no significant difference in glycemic improvement regardless of IMS severity at baseline.
In our cohort, lower IMS severity was associated with more weight loss in patients with obesity and T2D. Further studies are needed to understand T2D severity and its effect on semaglutide outcomes.
Beyond payment to the research staff by Mayo Clinic, this research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>38756106</pmid><doi>10.1016/j.eclinm.2024.102625</doi><tpages>1</tpages><orcidid>https://orcid.org/0009-0009-7595-9113</orcidid><orcidid>https://orcid.org/0000-0002-9389-6795</orcidid><orcidid>https://orcid.org/0000-0002-2322-7334</orcidid><orcidid>https://orcid.org/0000-0003-1829-7001</orcidid><orcidid>https://orcid.org/0000-0003-2286-489X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2589-5370 |
| ispartof | EClinicalMedicine, 2024-06, Vol.72, p.102625-102625, Article 102625 |
| issn | 2589-5370 2589-5370 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11096862 |
| source | BACON - Elsevier - GLOBAL_SCIENCEDIRECT-OPENACCESS; PubMed Central |
| subjects | Diabetes GLP-1 receptor agonists Individualized metabolic surgery score Obesity Semaglutide |
| title | Weight loss outcomes with semaglutide based on diabetes severity using the individualized metabolic surgery score |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T03%3A06%3A27IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Weight%20loss%20outcomes%20with%20semaglutide%20based%20on%20diabetes%20severity%20using%20the%20individualized%20metabolic%20surgery%20score&rft.jtitle=EClinicalMedicine&rft.au=Ghusn,%20Wissam&rft.date=2024-06-01&rft.volume=72&rft.spage=102625&rft.epage=102625&rft.pages=102625-102625&rft.artnum=102625&rft.issn=2589-5370&rft.eissn=2589-5370&rft_id=info:doi/10.1016/j.eclinm.2024.102625&rft_dat=%3Cproquest_pubme%3E3056666514%3C/proquest_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c367t-1ac78de25aabbc6f02fbb8e94c957fa0919eb2cb9de50f4f7d51698d38202b8c3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3056666514&rft_id=info:pmid/38756106&rfr_iscdi=true |